Abstract
Immune reconstitution disease caused by Mycobacterium avium complex (MAC) infection presenting shortly after the introduction of highly active antiretroviral therapy (HAART) has been reported with increasing frequency in persons with HIV-1 infection during the past several years. Several therapeutic modalities have been utilized for this entity, but the optimal means of treating MAC immune reconstitution disease remains unclear. We now describe a patient who underwent some of these therapies. We then review the therapeutic outcomes from the numerous case reports of this disorder. Finally, we propose recommendations and a clinical algorithm regarding the optimal means of treatment of MAC immune reconstitution disease during HIV-1 infection.
MeSH terms
-
AIDS-Related Opportunistic Infections / diagnosis*
-
AIDS-Related Opportunistic Infections / diagnostic imaging
-
AIDS-Related Opportunistic Infections / drug therapy
-
AIDS-Related Opportunistic Infections / surgery
-
Adult
-
Anti-Infective Agents / administration & dosage
-
Antiretroviral Therapy, Highly Active
-
Ciprofloxacin / administration & dosage
-
Clarithromycin / administration & dosage
-
Decision Trees
-
Diagnosis, Differential
-
HIV-1*
-
Humans
-
Male
-
Mycobacterium avium Complex
-
Mycobacterium avium-intracellulare Infection / diagnosis*
-
Mycobacterium avium-intracellulare Infection / diagnostic imaging
-
Mycobacterium avium-intracellulare Infection / drug therapy
-
Mycobacterium avium-intracellulare Infection / surgery
-
Radiography
Substances
-
Anti-Infective Agents
-
Ciprofloxacin
-
Clarithromycin